**Core Concept**
Crohn's disease is a type of inflammatory bowel disease (IBD) characterized by chronic inflammation of the gastrointestinal tract. The treatment of Crohn's disease often involves a combination of pharmacological agents, including aminosalicylates, corticosteroids, immunosuppressants, and biologics. The goal of treatment is to induce and maintain remission, improve quality of life, and prevent complications.

**Why the Correct Answer is Right**
The correct answer is a biologic agent that targets tumor necrosis factor-alpha (TNF-alpha), a cytokine involved in the inflammatory process. By blocking TNF-alpha, this drug reduces inflammation and promotes healing of the gastrointestinal tract. This mechanism is particularly effective in patients with moderate to severe Crohn's disease who have not responded to conventional therapy.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because aminosalicylates, such as sulfasalazine, are more effective in treating ulcerative colitis, another type of IBD. While they may provide some benefit in Crohn's disease, they are not the treatment of choice.
* **Option B:** This option is incorrect because corticosteroids, such as prednisone, can provide rapid relief of symptoms in Crohn's disease but are not suitable for long-term use due to side effects. They may be used in combination with other agents to induce remission.
* **Option D:** This option is incorrect because immunomodulators, such as azathioprine, are used to maintain remission in Crohn's disease but are not the first-line treatment for inducing remission.

**Clinical Pearl / High-Yield Fact**
When treating Crohn's disease, it is essential to consider the severity of symptoms, extent of disease, and presence of complications when selecting a treatment. Biologic agents like the correct answer are often reserved for patients with moderate to severe disease who have not responded to conventional therapy.

**Correct Answer:** C.